Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18111Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Milionis, H. J. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Achimastos, A. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.date.accessioned | 2015-11-24T18:50:36Z | - |
| dc.date.available | 2015-11-24T18:50:36Z | - |
| dc.identifier.issn | 0950-9240 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18111 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antihypertensive Agents/*pharmacology | en |
| dc.subject | Blood Pressure/*drug effects | en |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Endothelium, Vascular/drug effects | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | en |
| dc.subject | Hyperlipidemias/*drug therapy/physiopathology | en |
| dc.subject | Hypertension/*drug therapy/physiopathology | en |
| dc.subject | Renin-Angiotensin System/drug effects | en |
| dc.subject | Risk Factors | en |
| dc.title | Statins: another class of antihypertensive agents? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1038/sj.jhh.1002001 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16511505 | - |
| heal.identifier.secondary | http://www.nature.com/jhh/journal/v20/n5/pdf/1002001a.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | The assessment of global cardiovascular risk is an essential step in the management of atherosclerotic disease prevention. Among the risk factors to be addressed are hypertension and hyperlipidaemia; these commonly coexist. A neutral or lipid-friendly antihypertensive agent is probably useful in the presence of lipid abnormalities. Similarly, statins have been shown to decrease cardiovascular risk in hypertensive patients. There is also experimental and clinical evidence that statins have blood pressure (BP)-lowering effects. In this review, we discuss the beneficial effects of statins on BP, and provide an overview of the underlying pathophysiology. We also consider the evidence justifying the use of statins in the management of hypertensive patients. | en |
| heal.journalName | J Hum Hypertens | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Milionis-2006-Statins_ another cla.pdf | 184.66 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
